AFYREN Takes Full Control of Biorefinery as It Ramp-Up Production…

Event summary

AFYREN completed the full acquisition of its AFYREN NEOXY biorefinery for €11.3 million, concluding a decade-long partnership with SPI.
The company reported €2.3 million in revenue for 2025, down 21% from 2024, with a net loss of €14.4 million.
AFYREN NEOXY produced about 400 tons of bio-based acids in 2025, generating approximately €1 million in sales.
The company raised €23 million in November 2025 and €7 million in February 2026 from new long-term investors.

The big picture

AFYREN's full acquisition of its biorefinery marks a strategic shift towards greater autonomy and financial visibility. The move comes as the company navigates the typical 'J-curve' challenges of industrial ramp-ups, with significant investments aimed at optimizing production capacity and improving plant performance. This consolidation phase is critical for AFYREN to demonstrate the scalability of its technology before embarking on future expansion projects.

What we're watching

Production Scaling: Whether AFYREN can sustain the gradual increase in production and sales at NEOXY through 2026.
Financial Breakeven: The pace at which AFYREN achieves plant-level and Group-level financial breakeven with its first biorefinery.
Future Investments: How the company's ability to finance future plants will be affected by the consolidation of NEOXY and the removal of bottlenecks.